Difference in treatment outcomes between clinical trials and "real-life" clinical practice: ustekinumab in ulcerative colitis

United European Gastroenterol J. 2020 Feb;8(1):11-12. doi: 10.1177/2050640619900575.

Authors

Daniela Pugliese¹, Alessandro Armuzzi^{1

2}

Affiliations

¹ IBD Unit Presidio Columbus, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
² Università Cattolica del Sacro Cuore, Rome, Italy Corresponding author: Alessandro Armuzzi, Presidio Columbus Fondazione Policlinico Universitario A. Gemelli IRCCS - Universitá Cattolica, Via G. Moscati 31, Roma 00168, Italy Email: alearmuzzi@yahoo. com.

No abstract available

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal / pharmacology
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use
Biological Products / pharmacology
Biological Products / therapeutic use*
Colitis, Ulcerative / diagnosis
Colitis, Ulcerative / drug therapy*
Colitis, Ulcerative / immunology
Drug Approval
Drug Resistance
Drug Therapy, Combination / methods
Glucocorticoids / pharmacology
Glucocorticoids / therapeutic use
Humans
Induction Chemotherapy / methods
Patient Selection
Randomized Controlled Trials as Topic
Severity of Illness Index
Signal Transduction / drug effects
Signal Transduction / immunology
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Tumor Necrosis Factor-alpha / metabolism
Ustekinumab / pharmacology
Ustekinumab / therapeutic use*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Biological Products
Glucocorticoids
TNF protein, human
Tumor Necrosis Factor-alpha
golimumab
vedolizumab
Ustekinumab